keyword
MENU ▼
Read by QxMD icon Read
search

Direct antiviral agents

keyword
https://www.readbyqxmd.com/read/28088273/a-real-world-impact-of-cost-effectiveness-of-pegylated-interferon-ribavarin-regimens-on-treatment-na%C3%A3-ve-chronic-hepatitis-c-patients-in-taiwan
#1
Pei-Chien Tsai, Ta-Wei Liu, Meng-Hsuan Hsieh, Ming-Lun Yeh, Po-Cheng Liang, Yi-Hung Lin, Ching-I Huang, Chung-Feng Huang, Ming-Yen Hsieh, Nai-Jen Hou, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu
Treatments with pegylated interferon/ribavirin (PEG-IFN/RBV) has been standard-of-care in patients with chronic hepatitis C virus (HCV) (CHC) infection and reimbursed in Taiwan. However, the actual cost-effectiveness remains unclear. We aimed to evaluate a real-world cost-effectiveness for CHC patients treated with PEG-IFN/RBV by using a clinical cohort with linkage to the National Health Insurance Research Database of Taiwan. The total and itemized medical-care expenses of outpatient visits of 117 treatment-naïve CHC patients with linkage to the two million sampling of the National Health Insurance Research Database were collected...
January 2017: Kaohsiung Journal of Medical Sciences
https://www.readbyqxmd.com/read/28081594/management-of-direct-antiviral-agent-failures
#2
REVIEW
María Buti, Rafael Esteban
The current standard of care for patients with chronic hepatitis C virus (HCV) infection is a combination of direct-acting antiviral agents (DAAs). Most HCV patients treated with these drugs achieve viral elimination, but 1% to 15% fail to attain this objective. Treatment failures are usually related to relapse, and less often to on-treatment viral breakthrough. HCV drug resistant associated substitutions are detected in most patients who do not eliminate the virus. The risk of developing these variants depends on host- and virus-related factors, the properties of the drugs used, and the treatment strategies applied...
December 2016: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/28078644/eight-or-12-week-treatment-of-hepatitis-c-with-ledipasvir-sofosbuvir-real-world-experience-in-a-large-integrated-health-system
#3
Jennifer B Lai, Maxwell A Witt, Mary Patricia Pauly, Joanna Ready, Michael Allerton, Suk Seo, David J Witt
BACKGROUND: Second-generation direct-acting antiviral agents are integral to treatment of hepatitis C (HCV) infection. Eight-week courses of ledipasvir/sofosbuvir (LDV/SOF) have been supported in some studies, but data are limited on efficacy in real-world use. Controversy exists regarding applicability of clinical trials to real-world effectiveness. We report virologic responses of patients with HCV genotype 1 infection receiving LDV/SOF for 8 or 12 weeks in a large integrated healthcare system...
January 11, 2017: Drugs
https://www.readbyqxmd.com/read/28053914/resistance-to-direct-antiviral-agents-for-hepatitis-c-virus-infection-impact-on-clinical-practice
#4
EDITORIAL
Ana Belén Pérez, Federico García
No abstract text is available yet for this article.
December 2016: Germs
https://www.readbyqxmd.com/read/28052627/from-hcv-to-hbv-cure
#5
REVIEW
Raymond F Schinazi, Tarik Asselah
Approximately 170 million people are chronically infected with HCV and 350 million are chronically infected with HBV worldwide. It is estimated that more than one million patients die from complications related to chronic viral hepatitis, mainly HCC which is one of the most frequent cancers in many countries, especially Africa, the Middle East and Asia. HCV drug development has been impressive, and this revolution led to several direct-acting antiviral agents achieving an HCV cure after only 6-12 weeks...
January 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28052619/the-impact-of-direct-antiviral-agents-on-the-development-and-recurrence-of-hepatocellular-carcinoma
#6
REVIEW
María Reig, Loreto Boix, Jordi Bruix
Direct antiviral agents mark a major progress for the treatment of chronic hepatitis C virus infection. The rate of cure is higher than 90% in most populations and the safety profile is good. However, like any treatment, there are potential unexpected adverse events. Several reports have indicated that antiviral therapy may be associated with the reactivation of hepatitis B virus or the emergence of herpes virus in a time-related manner. Recently, several studies have described a potential unexpected incidence of hepatocellular carcinoma in treated patients, both in those without a prior history of cancer and those who have been successfully treated and were disease-free for different periods of time...
January 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28052618/the-future-of-liver-transplantation-for-viral-hepatitis
#7
REVIEW
François Durand, Claire Francoz
In hepatitis C virus (HCV)-infected patients, transplantation can be justified by decompensated cirrhosis, hepatocellular carcinoma (HCC) or both. During the last decade, HCV infection accounted for about 30% of the indications for transplantation in Europe and North America. Direct antiviral agents (DAAs) are highly effective at curing HCV, even in patients with end-stage cirrhosis. In the future, the incidence of HCV-related decompensated cirrhosis will continue to decrease. The incidence of HCC will also decrease, but a large cohort of patients with cirrhosis will still be at risk of developing HCC even after HCV has been cured...
January 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28049871/identification-of-genotype-2-hcv-in-serotype-1-hepatitis-c-patients-unresponsive-to-daclatasvir-plus-asunaprevir-treatment
#8
Jun Inoue, Atsushi Kanno, Yuta Wakui, Masahito Miura, Tomoo Kobayashi, Tatsuki Morosawa, Takayuki Kogure, Eiji Kakazu, Masashi Ninomiya, Yasuyuki Fujisaka, Teruyuki Umetsu, Satoshi Takai, Takuya Nakamura, Tooru Shimosegawa
It is important to determine the genotypes or serotypes of hepatitis C virus (HCV) in patients before treatment with direct-acting antiviral agents (DAAs), because the effects of DAAs differ among genotypes. In Japan, two tests for HCV typing are available clinically, but only serotyping, not genotyping, is approved by the public health insurance. Although most serotype-1 Japanese patients are infected with genotype 1b HCV, it is known that a small proportion of patients show different results from two typing methods...
2017: Tohoku Journal of Experimental Medicine
https://www.readbyqxmd.com/read/28049006/obatoclax-saliphenylhalamide-and-gemcitabine-inhibit-zika-virus-infection-in%C3%A2-vitro-and-differentially-affect-cellular-signaling-transcription-and-metabolism
#9
Suvi Kuivanen, Maxim M Bespalov, Jatin Nandania, Aleksandr Ianevski, Vidya Velagapudi, Jef K De Brabander, Denis E Kainov, Olli Vapalahti
An epidemic of Zika virus (ZIKV) infection associated with congenital abnormalities such as microcephaly, is ongoing in the Americas and the Pacific. Currently there are no approved therapies to treat this emerging viral disease. Here, we tested three cell-directed broad-spectrum antiviral compounds against ZIKV replication using human retinal pigment epithelial (RPE) cells and a low-passage ZIKV strain isolated from fetal brain. We found that obatoclax, SaliPhe, and gemcitabine inhibited ZIKV infections at noncytotoxic concentrations...
December 31, 2016: Antiviral Research
https://www.readbyqxmd.com/read/28045877/the-path-to-cancer-and-back-immune-modulation-during-hepatitis-c-virus-infection-progression-to-fibrosis-and-cancer-and-unexpected-roles-of-new-antivirals
#10
Jose D Debes, Robert J de Knegt, Andre Boonstra
Hepatitis C virus (HCV) infection affects over 130 million individuals worldwide, and it is the number 1 reason for liver transplantation in the United States. HCV infection progresses in a slow chronic fashion eliciting a strong but ineffective immune response, mainly characterized by NK cell dysfunction and T cell exhaustion. The chronic hepatic inflammation leads to liver fibrosis, cirrhosis and cancer in a significant number of patients. In recent years, groundbreaking research has led to the discovery of new HCV-specific direct acting antivirals (DAAs), which have an unprecedented efficacy to clear the virus, and establish a sustained virological response...
December 30, 2016: Transplantation
https://www.readbyqxmd.com/read/28043874/intrahepatic-innate-immune-response-pathways-are-down-regulated-in-untreated-chronic-hepatitis-b
#11
Fanny Lebossé, Barbara Testoni, Judith Fresquet, Floriana Facchetti, Enrico Galmozzi, Maëlenn Fournier, Valérie Hervieu, Pascale Berthillon, Françoise Berby, Isabelle Bordes, David Durantel, Massimo Levrero, Pietro Lampertico, Fabien Zoulim
BACKGROUND AND AIMS: Hepatitis B virus (HBV) persistence and the pathobiology of chronic HBV (CHB) infections result from the interplay between viral replication and host immune responses. Intrahepatic host genes expression and a comprehensive analysis of serum and liver HBV markers were performed in a large cohort of untreated CHB patients. PATIENTS AND METHODS: 105 CHB patients untreated at the time of liver biopsy (34 HBeAg(+) and 71 HBeAg(-)) were analysed for the intrahepatic expression profile of 67 genes belonging to multiple innate immunity pathways...
December 30, 2016: Journal of Hepatology
https://www.readbyqxmd.com/read/28027917/profile-of-anti-herpetic-action-of-asp2151-amenamevir-as-a-helicase-primase-inhibitor
#12
Misako Yajima, Hiroshi Yamada, Masaya Takemoto, Tohru Daikoku, Yoshihiro Yoshida, Tan Long, Tomoko Okuda, Kimiyasu Shiraki
The antiherpetic drugs acyclovir (ACV, valaciclovir) and penciclovir (famciclovir) are phosphorylated by viral thymidine kinase and terminate DNA synthesis. ASP2151 (amenamevir) and foscavir (PFA) directly inhibit viral helicase-primase and DNA polymerase, respectively, and inhibit replication of herpes simplex virus (HSV) and varicella-zoster virus. ACV, ASP2151, and PFA all inhibit HSV with a different mechanism of action and as a consequence, the kinetics of viral DNA accumulation and progeny virus production differ...
December 24, 2016: Antiviral Research
https://www.readbyqxmd.com/read/28013117/hepatocellular-carcinoma-is-the-most-common-indication-for-liver-transplantation-and-placement-on-the-waitlist-in-the-united-states
#13
Ju Dong Yang, Joseph J Larson, Kymberly D Watt, Alina M Allen, Russell H Wiesner, Gregory J Gores, Lewis R Roberts, Julie A Heimbach, Michael D Leise
BACKGROUND & AIMS: Management strategies for patients with hepatitis C virus (HCV) infection and hepatocellular carcinoma (HCC) have changed, along with liver allocation policies based on model for end-stage liver disease (MELD) score. We investigated etiologic-specific trends in liver transplantation in the United States (US) during different time periods. METHODS: We performed a retrospective study, using the United Network for Organ Sharing/ Organ Procurement and Transplantation Network registry data to identify all adult patients registered for liver transplantation in the US from January 1, 2004 through December 31, 2015...
December 21, 2016: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28009781/safety-and-efficacy-of-treatment-of-hepatitis-c-in-kidney-transplant-recipients-with-directly-acting-antiviral-agents
#14
Michelle Lubetzky, Soohwan Chun, Andrew Joelson, Maria Coco, Layla Kamal, Maria Ajaimy, Paul Gaglio, Enver Akalin, Graciela Deboccardo
BACKGROUND: With the development of all oral, interferon-free directly acting antiviral (DAA) medications, treatment of Hepatitis C infection (HCV) in renal transplant recipients is possible, but limited data exists on its safety and efficacy. METHODS: We performed a retrospective cohort analysis of patients transplanted at our center with HCV who have been started on DAAs. Primary endpoints included sustained virologic response (SVR) as defined as negative viral load at 12 weeks post completion of therapy and allograft function...
December 22, 2016: Transplantation
https://www.readbyqxmd.com/read/28004616/age-and-time-dependent-prevalence-and-incidence-of-hepatitis-c-virus-infection-in-drug-users-in-france-2004-2011-model-based-estimation-from-two-national-cross-sectional-serosurveys
#15
L Leon, S Kasereka, F Barin, C Larsen, L Weill-Barillet, X Pascal, S Chevaliez, J Pillonel, M Jauffret-Roustide, Y LE Strat
Hepatitis C virus (HCV) infection is a public health issue worldwide. Injecting drug use remains the major mode of transmission in developed countries. Monitoring the HCV transmission dynamic over time is crucial, especially to assess the effect of harm reduction measures in drug users (DU). Our objective was to estimate the prevalence and incidence of HCV infection in DU in France using data from a repeated cross-sectional survey conducted in 2004 and 2011. Age- and time-dependent HCV prevalence was estimated through logistic regression models adjusted for HIV serostatus or injecting practices...
December 22, 2016: Epidemiology and Infection
https://www.readbyqxmd.com/read/27990496/lupus-like-immune-complex-mediated-glomerulonephritis-in-patients-with-hepatitis-c-virus-infection-treated-with-oral-interferon-free-direct-acting-antiviral-therapy
#16
Meghan E Sise, Jessica Wisocky, Ivy A Rosales, Donald Chute, Jacinta A Holmes, Kristin M Corapi, Jodie L Babitt, Jessica S Tangren, Nikroo Hashemi, Andrew L Lundquist, Winfred W Williams, David B Mount, Karin L Andersson, Helmut G Rennke, R Neal Smith, Robert Colvin, Ravi I Thadhani, Raymond T Chung
Novel, all-oral interferon-free direct-acting antiviral agents have revolutionized the management of hepatitis C virus (HCV) infection by producing exceptional cure rates with minimal adverse events. While provocation or exacerbation of autoimmunity has been reported in HCV-infected patients receiving interferon, this phenomenon has not been reported in patients receiving interferon-free HCV therapy. We report the occurrence of three cases of lupus-like immune complex-mediated glomerulonephritis occurring shortly after exposure to sofosbuvir-based direct-acting antiviral therapies...
September 2016: KI Reports
https://www.readbyqxmd.com/read/27978936/-current-status-of-treatment-of-chronic-hepatitis-c-and-related-challenges-in-the-pre-daa-era-in-china
#17
P Hu, H Ren
The condition of chronic hepatitis C is becoming more and more serious in China, and its disease burden and social and economic burdens are growing heavier. Currently, the standard regimen for the treatment of chronic hepatitis C in China is the PR regimen, namely pegylated interferon combined with ribavirin; however, there are still many shortcomings in this regimen. In the world, there is rapid clinical progress in direct-acting antiviral agents (DAAs) for the treatment of hepatitis C, and DAAs will soon be approved and marketed in China, ushering the "DAA Era" of hepatitis C treatment...
November 20, 2016: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/27976461/safety-and-efficacy-of-direct-acting-antivirals-for-the-treatment-of-chronic-hepatitis-c-in-a-real-world-population-aged-65-years-and-older
#18
Fabio Conti, Stefano Brillanti, Federica Buonfiglioli, Ranka Vukotic, Maria Cristina Morelli, Claudine Lalanne, Marco Massari, Francesco Giuseppe Foschi, Veronica Bernabucci, Ilaria Serio, Gian Maria Prati, Elisa Negri, Lorenzo Badia, Paolo Caraceni, Paolo Muratori, Giovanni Vitale, Alberto Porro, Marta Morotti, Giuseppe Mazzella, Pietro Andreone
The availability of direct acting antiviral agents (DAA) regimens has expanded the pool of patients eligible for treatment. However, data on the virological response and tolerability of DAAs in elderly patients are lacking. We evaluated the efficacy and safety of DAAs in patients with advanced fibrosis/cirrhosis in real-life practice with the focus on those aged ≥65 years. Between January and December 2015, all consecutive patients with HCV-related advanced fibrosis/cirrhosis treated with DAA at eleven tertiary referral centers in Emilia Romagna (Italy) were enrolled...
December 15, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27959851/-screening-diagnosis-and-treatment-of-chronic-hepatitis-c-in-clinical-practice
#19
Ezequiel Ridruejo, Hugo Fainboim, Alejandra Villamil
Chronic hepatitis C (HCV) is a global health problem. Worldwide, 170 million people are chronically infected. In Latin America its prevalence is estimated between 1.0 and 2.3%, and in Argentina between 1.0 and 1.5%. Treatment efficacy has considerably improved in the last 2 or 3 years. Sustained virological response (SVR) rates around 90-95% can be achieved with the new direct acting antiviral agents (DAAs) currently available, with few side effects. It is necessary to increase the number of diagnosed patients, linking them to adequate management and treatment...
2016: Medicina
https://www.readbyqxmd.com/read/27941432/immune-reconstitution-following-hcv-clearance-with-direct-antiviral-agents-potential-consequences-for-patients-with-hcc
#20
Jens M Werner, Akinbami Adenugba, Ulrike Protzer
Recent introduction of all-oral direct acting antiviral treatment has revolutionized care of patients with chronic hepatitis C virus infection. Since patients with different liver disease stages have been treated with great success including those awaiting liver transplantation, therapy has been extended to patients with hepatocellular carcinoma as well. From observational studies among compensated cirrhotic hepatitis C patients treated with interferon-containing regimens, it would have been expected that the rate of hepatocellular carcinoma occurrence is markedly decreased after a sustained virological response...
December 8, 2016: Transplantation
keyword
keyword
12534
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"